Understanding the impact of metastatic colorectal cancer on muscle and bone health
The musculoskeletal cost of metastatic colorectal cancer
This study is looking at how advanced colorectal cancer causes weight loss and muscle weakness, and it aims to find out if a hormone called FGF21 plays a role in this, so we can discover new ways to help patients feel better and maintain their strength.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11104717 on NIH RePORTER |
What this research studies
This research investigates how metastatic colorectal cancer leads to cachexia, a condition that causes significant muscle and bone loss, negatively affecting patients' quality of life. The study aims to identify specific biological factors, particularly the hormone FGF21, that contribute to this wasting syndrome. By examining the metabolic changes in patients with advanced colorectal cancer, the research seeks to uncover potential targets for treatment to mitigate muscle and bone deterioration. The approach includes both laboratory studies and patient data analysis to understand the mechanisms behind cachexia.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic colorectal cancer who are experiencing symptoms of cachexia.
Not a fit: Patients with early-stage colorectal cancer or those without cachexia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help preserve muscle and bone health in patients with metastatic colorectal cancer.
How similar studies have performed: Previous research has indicated that targeting metabolic pathways in cachexia may yield promising results, suggesting that this approach could be effective.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Huot, Joshua — Indiana University Indianapolis
- Study coordinator: Huot, Joshua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.